Autoimmune Diseases, Checkpoint Inhibitor, Immunotherapy
Conditions
Brief summary
Patients with cancer and concurrent autoimmune diseases (AID) have been universally excluded from clinical trials evaluating immunotherapy. Data on the safety and efficacy of checkpoint inhibitors in patients with underlying AID is limited. The investigators performed a retrospective multicenter review of medical records of patients with diverse tumor types and underlying AID who received checkpoint inhibitors at Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG). The primary endpoint was progression-free survival (PFS).
Interventions
Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease
Sponsors
Hellenic Cooperative Oncology Group
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or older * Patients with cancer * Patients with autoimmune disease * Treated at HeCOG-affiliated Departments of Oncology * Early-stage or metastatic
Exclusion criteria
* diagnosis of the autoimmune disease after initiation of immunotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival | Through the completion of the study, for an average of 6 months |
Countries
Greece
Outcome results
None listed